LONDON (ShareCast) - (Sharecast News) - AIM-listed Evgen Pharma said on Friday that it is in talks with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, in which it would provide support with its lead product, SFX-01.
The lead product from Evgen, which is a clinical stage drug development company focusing on the treatment of cancer and neurological conditions, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The statement was made in response to a rise in the share price in recent days.

"A further announcement will be made if these discussions are successful," it said.

At 1305 BST, the shares were up 27% at 14.48p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE